Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03897881
Title An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Patients With High-Risk Melanoma (KEYNOTE-942)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ModernaTX, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS


No variant requirements are available.